- Home
- CREV vs GTBP Comparison
CREV vs GTBP Comparison
Compare CREV & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CREV | GTBP |
|---|---|---|
| Founded | 2007 | 1965 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CREV | GTBP |
|---|---|---|
| Price | $2.53 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 141.7K | ★ 1.6M |
| Earning Date | 01-30-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,677,475.00 | N/A |
| Revenue This Year | $40.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.77 | N/A |
| 52 Week Low | $1.48 | $0.54 |
| 52 Week High | $9.45 | $3.85 |
Technical Indicators
Market Signals| Indicator | CREV | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.65 | 61.63 |
| Support Level | $1.57 | $0.63 |
| Resistance Level | $1.77 | $0.75 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 69.96 | 83.19 |
Price Performance
Historical ComparisonAbout CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.